mp.weixin.qq.com· 允英·· 6 hours agoPickScore66
Broad-Spectrum RAS Inhibitor Daraxonrasib Wins FDA Approval in Metastatic Pancreatic Cancer
不止 KRAS G12C！广谱RAS抑制剂斩获胰腺癌适应症，肺癌领域疗效亮眼
In brief
The broad-spectrum RAS inhibitor daraxonrasib received FDA approval on August 26 for metastatic pancreatic cancer in adults who have received at least one prior systemic therapy or are not suitable for multi-drug combination systemic therapy. Unlike KRAS G12C inhibitors, it covers mutations including G12V, G12D, G13 and Q61, and the article also notes strong efficacy in lung cancer.
Why it matters
First approval extending RAS inhibition beyond KRAS G12C to multiple RAS mutations in pancreatic cancer.
Source: mp.weixin.qq.com · mp.weixin.qq.com